Contents

Current Pharmaceutical Design, Volume 11 - Number 26

Editorial [Hot Topic: Alzheimerss Disease, Dementia and Cognitive Decline (Executive Editors: J.E. Starrett, Jr. and G.S. Poindexter)]

, 11(26): 3327

J. E. Starrett, Jr. and G. S. Poindexter


DOI: 10.2174/138161205774370816




Phosphodiesterase Inhibitors for Cognitive Enhancement

, 11(26): 3329 - 3334

G. M. Rose, A. Hopper, M. De Vivo and A. Tehim


DOI: 10.2174/138161205774370799




The Dualistic Nature of Immune Modulation In Alzheimers Disease: Lessons from the Transgenic Models

, 11(26): 3335 - 3352

R. B. Nelson


DOI: 10.2174/138161205774370843




Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimers Disease

, 11(26): 3353 - 3361

J. W. Clader and Y. Wang


DOI: 10.2174/138161205774370762




γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease

, 11(26): 3363 - 3382

I. Churcher and D. Beher


DOI: 10.2174/138161205774370771




Progress in the Discovery of BACE Inhibitors

, 11(26): 3383 - 3404

L. A. Thompson, J. J. Bronson and F. C. Zusi


DOI: 10.2174/138161205774370825




RNA Interference-Based Gene Silencing in Mice: The Development of a Novel Therapeutical Strategy

, 11(26): 3405 - 3419

B. Spankuch and K. Strebhardt


DOI: 10.2174/138161205774370834




Participation of the Cannabinoid System in the Regulation of Emotional- Like Behaviour

, 11(26): 3421 - 3429

O. Valverde


DOI: 10.2174/138161205774370780




Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer

, 11(26): 3431 - 3447

J. Claria and M. Romano


DOI: 10.2174/138161205774370753




FLT3 and Acute Myelogenous Leukemia: Biology, Clinical Significance and Therapeutic Applications

, 11(26): 3449 - 3457

A. S. Advani


DOI: 10.2174/138161205774370807




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science